Rhenman & Partners Asset Management AB Has $2.45 Million Position in Janux Therapeutics, Inc. $JANX

Rhenman & Partners Asset Management AB boosted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 81.6% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 100,127 shares of the company’s stock after purchasing an additional 45,000 shares during the period. Rhenman & Partners Asset Management AB owned about 0.17% of Janux Therapeutics worth $2,447,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its position in Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in shares of Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock valued at $85,000 after acquiring an additional 1,011 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after acquiring an additional 2,502 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Janux Therapeutics by 25.6% in the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after acquiring an additional 820 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Janux Therapeutics by 185.1% in the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock worth $177,000 after acquiring an additional 4,982 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Trending Headlines about Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term 2026 quarterly EPS estimates (Q1–Q4 2026) and improved its FY2026 loss forecast (from ($2.70) to ($2.40)), while maintaining a “Buy” rating and a $45 price target — a supportive analyst endorsement that can help underpin the stock. HC Wainwright raises near‑term estimates
• Neutral Sentiment: Major media/analyst roundups (reported by Globe and Mail) listed Janux among healthcare names receiving analyst commentary today — this amplifies visibility but is informational rather than a direct catalyst. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright trimmed several longer‑term EPS forecasts (FY2027–FY2029 and FY2028 notably worse vs prior estimates), increasing uncertainty about Janux’s multi‑year trajectory and dampening upside despite the high target — a factor that likely contributed to selling pressure. HC Wainwright trims long‑term estimates

Janux Therapeutics Stock Down 0.9%

Shares of JANX stock opened at $13.84 on Friday. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34. The firm has a market cap of $841.89 million, a PE ratio of -7.56 and a beta of 2.88. The stock has a 50 day moving average of $13.68 and a 200-day moving average of $20.32.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.14. The company had revenue of $7.88 million during the quarter, compared to analyst estimates of $0.08 million. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 8,072 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares of the company’s stock, valued at $3,912,802.86. This represents a 2.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Zachariah Mciver sold 2,714 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the transaction, the insider owned 23,286 shares in the company, valued at approximately $319,716.78. The trade was a 10.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 19,033 shares of company stock worth $261,323. 8.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on JANX. HC Wainwright reduced their price objective on Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Cantor Fitzgerald cut their price target on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Stifel Nicolaus reduced their price target on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Finally, Wedbush reissued an “outperform” rating and issued a $45.00 price target (down from $76.00) on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Janux Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $56.91.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.